Anti-Human CD3 x BCMA (Teclistamab) – Fc Muted™
Anti-Human CD3 x BCMA (Teclistamab) – Fc Muted™
Product No.: C975
- -
- -
Product No.C975 Clone JNJ-64007957 Target CD3 x BCMA Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names CD3ε: T-cell surface antigen T3/Leu-4 epsilon chain, T3E BCMA: tumor necrosis factor receptor superfamily member 17, CD269 Isotype Human IgG4κ Applications Agonist , FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen BCMA-Fc recombinant protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? Agonist, FA, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as
the therapeutic antibody Teclistamab. Teclistamab simultaneously binds CD3ε and B cell
maturation antigen (BCMA). Background CD3 is an invariant antigen of the T cell TCR (T cell receptor)1. BCMA is a member of the tumor necrosis factor family of receptors that regulates B cell maturation, proliferation, and survival by activating p38/NF-κB and inducing upregulation of antiapoptotic proteins2. BCMA is highly expressed on multiple myeloma (MM) cells and is therefore a target of cancer immunotherapy. Teclistamab is a humanized IgG4-proline, alanine, alanine (IgG4-PAA) DuoBody CD3xBCMA Bispecific T cell Engager (BiTE) antibody developed for treatment of MM2,3. Teclistamab treatment redirects CD3+ T cells to BCMA-expressing MM cells, leading to the secretion of perforin and certain granzymes from the cytotoxic T cells and ultimately inducing antibody-dependent cell cytotoxicity and tumor cell death of the BCMA-expressing B cells. The process is not specific and MHC I molecules on antigen presenting cells are not involved3. Teclistamab treatment also leads to the secretion of interferon-γ, TNF-α, IL-2, IL-6, IL-8, and IL-102 cytokines are induced2,3. Additionally, activity is increased by the γ-secretase inhibitor LY-4115752. Teclistamab was generated by immunizing OmniRats (Open Monoclonal Technology) with BCMA-Fc recombinant protein and re-cloning hits on a relatively silent IgG4-PAA scaffold2. A controlled Fab-arm exchange of a BCMA antibody and a CD3 parental antibody derived from SP34 was then performed. The Fc region of Teclistamab contains S228P/L234A/L235A mutations to minimize its immunological effector functions. Teclistamab has been approved for treatment of MM in patients who demonstrate disease progression despite treatment3. Antigen Distribution CD3ε is a T cell surface glycoprotein. BCMA is predominantly expressed
on the surface of terminally differentiated B cells and is overexpressed and activated on
malignant multiple myeloma B cells (plasmablasts and plasma cells). Ligand/Receptor CD3ε: TCR <br>
BCMA: TNFSF13B/BLyS/BAFF, TNFSF13/APRIL, TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6 Research Area Adaptive Immunity . Cancer . Immuno-Oncology References & Citations1 Mariuzza RA, Agnihotri P, Orban J. J Biol Chem. 295(4):914-925. 2020. 2 Pillarisetti K, Powers G, Luistro L, et al. Blood Adv. 4(18):4538-4549. 2020. 3 Kang C. Drugs. 82(16):1613-1619. 2022 4 Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Lancet. 398(10301):665-674. 2021. 5 Moreau P, Garfall AL, van de Donk NWCJ, et al. N Engl J Med. 387(6):495-505. 2022. 6 Glatte B, Wenk K, Grahnert A, et al. Blood Adv. 7(15):3842-3845. 2023. 7 Miao X, Wu LS, Lin SXW, et al. Target Oncol. 18(5):667-684. 2023. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
C970 | |
C975 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.